{"pmid":32473642,"title":"Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19.","text":["Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19.","Ann Clin Microbiol Antimicrob","Sharun, Khan","Dhama, Kuldeep","Patel, Shailesh Kumar","Pathak, Mamta","Tiwari, Ruchi","Singh, Bhoj Raj","Sah, Ranjit","Bonilla-Aldana, D Katterine","Rodriguez-Morales, Alfonso J","Leblebicioglu, Hakan","32473642"],"journal":"Ann Clin Microbiol Antimicrob","authors":["Sharun, Khan","Dhama, Kuldeep","Patel, Shailesh Kumar","Pathak, Mamta","Tiwari, Ruchi","Singh, Bhoj Raj","Sah, Ranjit","Bonilla-Aldana, D Katterine","Rodriguez-Morales, Alfonso J","Leblebicioglu, Hakan"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32473642","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1186/s12941-020-00368-w","keywords":["2019-ncov","covid-19","coronavirus","ivermectin","sars-cov-2","therapeutics"],"topics":["Treatment"],"weight":1,"_version_":1668341932678447104,"score":9.490897,"similar":[{"pmid":32462282,"title":"Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.","text":["Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.","Ivermectin is an antiparasitic drug that has shown also an effective pharmacological activity towards various infective agents, including viruses. This paper proposes an alternative mechanism of action for this drug that makes it capable of having an antiviral action, also against the novel coronavirus, in addition to the processes already reported in literature.","Naunyn Schmiedebergs Arch Pharmacol","Rizzo, Emanuele","32462282"],"abstract":["Ivermectin is an antiparasitic drug that has shown also an effective pharmacological activity towards various infective agents, including viruses. This paper proposes an alternative mechanism of action for this drug that makes it capable of having an antiviral action, also against the novel coronavirus, in addition to the processes already reported in literature."],"journal":"Naunyn Schmiedebergs Arch Pharmacol","authors":["Rizzo, Emanuele"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462282","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s00210-020-01902-5","keywords":["antiviral","covid-19","ionophore","ivermectin","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521475067906,"score":91.09442},{"pmid":32378737,"title":"The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19.","text":["The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19.","Caly, Druce (1) reported that ivermectin inhibited SARS-CoV-2 in vitro for up to 48 h using ivermectin at 5muM. The concentration resulting in 50% inhibition (IC50, 2 microM) was >35x higher than the maximum plasma concentration (Cmax) after oral administration of the approved dose of ivermectin when given fasted. Simulations were conducted using an available population pharmacokinetic model to predict total (bound and unbound) and unbound plasma concentration-time profiles after a single and repeat fasted administration of the approved dose of ivermectin (200 mug/kg), 60 mg, and 120 mg. Plasma total Cmax was determined and then multiplied by the lung:plasma ratio reported in cattle to predict the lung Cmax after administration of each single dose. Plasma ivermectin concentrations of total (bound and unbound) and unbound concentrations do not reach the IC50 , even for a dose level 10x higher than the approved dose. Even with the high lung:plasma ratio, ivermectin is unlikely to reach the IC50 in lungs after single oral administration of the approved dose (predicted lung: 0.0873 microM) or at doses 10x higher that the approved dose administered orally (predicted lung: 0.820 microM). In summary, the likelihood of a successful clinical trial using the approved dose of ivermectin is low. Combination therapy should be evaluated in vitro. Re-purposing drugs for use in COVID-19 treatment is an ideal strategy but is only feasible when product safety has been established and experiments of re-purposed drugs are conducted at clinically relevant concentrations.","Clin Pharmacol Ther","Schmith, Virginia D","Zhou, Jie Jessie","Lohmer, Lauren Rl","32378737"],"abstract":["Caly, Druce (1) reported that ivermectin inhibited SARS-CoV-2 in vitro for up to 48 h using ivermectin at 5muM. The concentration resulting in 50% inhibition (IC50, 2 microM) was >35x higher than the maximum plasma concentration (Cmax) after oral administration of the approved dose of ivermectin when given fasted. Simulations were conducted using an available population pharmacokinetic model to predict total (bound and unbound) and unbound plasma concentration-time profiles after a single and repeat fasted administration of the approved dose of ivermectin (200 mug/kg), 60 mg, and 120 mg. Plasma total Cmax was determined and then multiplied by the lung:plasma ratio reported in cattle to predict the lung Cmax after administration of each single dose. Plasma ivermectin concentrations of total (bound and unbound) and unbound concentrations do not reach the IC50 , even for a dose level 10x higher than the approved dose. Even with the high lung:plasma ratio, ivermectin is unlikely to reach the IC50 in lungs after single oral administration of the approved dose (predicted lung: 0.0873 microM) or at doses 10x higher that the approved dose administered orally (predicted lung: 0.820 microM). In summary, the likelihood of a successful clinical trial using the approved dose of ivermectin is low. Combination therapy should be evaluated in vitro. Re-purposing drugs for use in COVID-19 treatment is an ideal strategy but is only feasible when product safety has been established and experiments of re-purposed drugs are conducted at clinically relevant concentrations."],"journal":"Clin Pharmacol Ther","authors":["Schmith, Virginia D","Zhou, Jie Jessie","Lohmer, Lauren Rl"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378737","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/cpt.1889","keywords":["covid-19","ivermectin","dose-response","pharmacokinetics"],"locations":["Plasma"],"e_drugs":["Ivermectin"],"topics":["Treatment"],"weight":1,"_version_":1666262687683706880,"score":86.75638},{"pmid":32479893,"title":"Ivermectin: repurposing a multipurpose drug for Venezuela's humanitarian crisis.","text":["Ivermectin: repurposing a multipurpose drug for Venezuela's humanitarian crisis.","For decades, Ivermectin (IVM) has been recognized as a robust antiparasitic drug with excellent tolerance and safety profiles. Historically it has been used as the drug of choice for onchocerciasis and lymphatic filariasis global elimination programs. IVM is also a standard treatment against intestinal helminths and ectoparasites given its action as an oral insecticide. The current humanitarian crisis in Venezuela is a regional public health threat that requires immediate action. Venezuela's public health system has now crumbled due to a 70% shortage of medicines in public hospitals, low vaccination campaigns, and the massive exodus of medical personnel. Herein we discuss the repurposing of IVM to attenuate the burden imposed by the most prevalent neglected tropical diseases (NTDs) in Venezuela including soil-transmitted helminths, ectoparasites and, possibly, vector-borne diseases such as malaria. Additionally, novel experimental evidence has shown that IVM is active and efficacious against Chagas disease, Leishmaniases, arboviruses, and SARS-CoV-2 in vitro. In crisis-hit Venezuela, all of the aforementioned infectious diseases are public health emergencies that have been long ignored and that also require immediate attention. IVM's versatile nature could serve as a powerful tool to tackle the multiple overlapping endemic and emergent diseases that affect Venezuela today. The repurposing of this multipurpose drug would be without a doubt a timely therapeutical approach to help mitigate the tremendous burden of NTDs nationwide.","Int J Antimicrob Agents","Perez-Garcia, Luis A","Mejias-Carpio, Isis E","Delgado-Noguera, Lourdes A","Manzanarez-Motezuma, Jean P","Escalona-Rodriguez, Maria A","Sordillo, Emilia M","Mogollon-Rodriguez, Euler A","Hernandez-Pereira, Carlos E","Marquez-Colmenarez, Marilianna C","Paniz-Mondolfi, Alberto E","32479893"],"abstract":["For decades, Ivermectin (IVM) has been recognized as a robust antiparasitic drug with excellent tolerance and safety profiles. Historically it has been used as the drug of choice for onchocerciasis and lymphatic filariasis global elimination programs. IVM is also a standard treatment against intestinal helminths and ectoparasites given its action as an oral insecticide. The current humanitarian crisis in Venezuela is a regional public health threat that requires immediate action. Venezuela's public health system has now crumbled due to a 70% shortage of medicines in public hospitals, low vaccination campaigns, and the massive exodus of medical personnel. Herein we discuss the repurposing of IVM to attenuate the burden imposed by the most prevalent neglected tropical diseases (NTDs) in Venezuela including soil-transmitted helminths, ectoparasites and, possibly, vector-borne diseases such as malaria. Additionally, novel experimental evidence has shown that IVM is active and efficacious against Chagas disease, Leishmaniases, arboviruses, and SARS-CoV-2 in vitro. In crisis-hit Venezuela, all of the aforementioned infectious diseases are public health emergencies that have been long ignored and that also require immediate attention. IVM's versatile nature could serve as a powerful tool to tackle the multiple overlapping endemic and emergent diseases that affect Venezuela today. The repurposing of this multipurpose drug would be without a doubt a timely therapeutical approach to help mitigate the tremendous burden of NTDs nationwide."],"journal":"Int J Antimicrob Agents","authors":["Perez-Garcia, Luis A","Mejias-Carpio, Isis E","Delgado-Noguera, Lourdes A","Manzanarez-Motezuma, Jean P","Escalona-Rodriguez, Maria A","Sordillo, Emilia M","Mogollon-Rodriguez, Euler A","Hernandez-Pereira, Carlos E","Marquez-Colmenarez, Marilianna C","Paniz-Mondolfi, Alberto E"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479893","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.ijantimicag.2020.106037","keywords":["ivermectin","venezuela","crisis","endemic","epidemic","humanitarian","multipurpose"],"locations":["Venezuela","Venezuela","Venezuela","Venezuela","Venezuela","Venezuela"],"countries":["Venezuela, Bolivarian Republic of"],"countries_codes":["VEN|Venezuela, Bolivarian Republic of"],"topics":["Treatment"],"weight":1,"_version_":1668437835180408832,"score":81.24001},{"pmid":32322397,"pmcid":"PMC7175902","title":"Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance.","text":["Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance.","Alarming situation has been caused due to the emergence of COVID-19 infection around the world. There is an urgency of developing a therapeutic strategy in order to control the spread of COVID-19. Towards that initiative, potential drugs like hydroxychloroquine, ivermectin and azithromycin have been tested by diverse group of researchers worldwide for their potential against novel coronavirus. The present report presents together the comprehensive knowledge derived from the major researches about the above drugs altogether in context of the current health emergency around the world. Hydroxychloroquine and ivermectin were known to act by creating the acidic environment and inhibiting the importin (IMPalpha/beta1) mediated viral import. Azithromycin was found to act similar to the hydroxychloroquine as an acidotropic lipophilic weak base. All the three categories of drugs seemed to potentially act against novel coronavirus infection. However, their efficacies need to be studied in detail individually and in combination in-vivo in order to combat COVID-19 infection.","New Microbes New Infect","Choudhary, Renuka","Sharma, Anil K","Choudhary, Renuka","32322397"],"abstract":["Alarming situation has been caused due to the emergence of COVID-19 infection around the world. There is an urgency of developing a therapeutic strategy in order to control the spread of COVID-19. Towards that initiative, potential drugs like hydroxychloroquine, ivermectin and azithromycin have been tested by diverse group of researchers worldwide for their potential against novel coronavirus. The present report presents together the comprehensive knowledge derived from the major researches about the above drugs altogether in context of the current health emergency around the world. Hydroxychloroquine and ivermectin were known to act by creating the acidic environment and inhibiting the importin (IMPalpha/beta1) mediated viral import. Azithromycin was found to act similar to the hydroxychloroquine as an acidotropic lipophilic weak base. All the three categories of drugs seemed to potentially act against novel coronavirus infection. However, their efficacies need to be studied in detail individually and in combination in-vivo in order to combat COVID-19 infection."],"journal":"New Microbes New Infect","authors":["Choudhary, Renuka","Sharma, Anil K","Choudhary, Renuka"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32322397","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.nmni.2020.100684","keywords":["azithromycin","coronavirus","hydroxychloroquine","ivermectin"],"e_drugs":["Hydroxychloroquine","Azithromycin","Ivermectin"],"topics":["Treatment"],"weight":1,"_version_":1666138493794910208,"score":79.50878},{"pmid":32036774,"pmcid":"PMC7054940","title":"Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments.","text":["Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments.","Coronaviruses are the well-known cause of severe respiratory, enteric and systemic infections in a wide range of hosts including man, mammals, fish, and avian. The scientific interest on coronaviruses increased after the emergence of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) outbreaks in 2002-2003 followed by Middle East Respiratory Syndrome CoV (MERS-CoV). This decade's first CoV, named 2019-nCoV, emerged from Wuhan, China, and declared as 'Public Health Emergency of International Concern' on January 30(th), 2020 by the World Health Organization (WHO). As on February 4, 2020, 425 deaths reported in China only and one death outside China (Philippines). In a short span of time, the virus spread has been noted in 24 countries. The zoonotic transmission (animal-to-human) is suspected as the route of disease origin. The genetic analyses predict bats as the most probable source of 2019-nCoV though further investigations needed to confirm the origin of the novel virus. The ongoing nCoV outbreak highlights the hidden wild animal reservoir of the deadly viruses and possible threat of spillover zoonoses as well. The successful virus isolation attempts have made doors open for developing better diagnostics and effective vaccines helping in combating the spread of the virus to newer areas.","Vet Q","Malik, Yashpal Singh","Sircar, Shubhankar","Bhat, Sudipta","Sharun, Khan","Dhama, Kuldeep","Dadar, Maryam","Tiwari, Ruchi","Chaicumpa, Wanpen","32036774"],"abstract":["Coronaviruses are the well-known cause of severe respiratory, enteric and systemic infections in a wide range of hosts including man, mammals, fish, and avian. The scientific interest on coronaviruses increased after the emergence of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) outbreaks in 2002-2003 followed by Middle East Respiratory Syndrome CoV (MERS-CoV). This decade's first CoV, named 2019-nCoV, emerged from Wuhan, China, and declared as 'Public Health Emergency of International Concern' on January 30(th), 2020 by the World Health Organization (WHO). As on February 4, 2020, 425 deaths reported in China only and one death outside China (Philippines). In a short span of time, the virus spread has been noted in 24 countries. The zoonotic transmission (animal-to-human) is suspected as the route of disease origin. The genetic analyses predict bats as the most probable source of 2019-nCoV though further investigations needed to confirm the origin of the novel virus. The ongoing nCoV outbreak highlights the hidden wild animal reservoir of the deadly viruses and possible threat of spillover zoonoses as well. The successful virus isolation attempts have made doors open for developing better diagnostics and effective vaccines helping in combating the spread of the virus to newer areas."],"journal":"Vet Q","authors":["Malik, Yashpal Singh","Sircar, Shubhankar","Bhat, Sudipta","Sharun, Khan","Dhama, Kuldeep","Dadar, Maryam","Tiwari, Ruchi","Chaicumpa, Wanpen"],"date":"2020-02-11T11:00:00Z","year":2020,"_id":"32036774","source":"PubMed","week":"20207|Feb 10 - Feb 16","doi":"10.1080/01652176.2020.1727993","keywords":["2019-ncov","coronavirus","middle east respiratory syndrome cov","public health emergency","severe acute respiratory syndrome cov","genetic analyses","reservoir host","therapeutics","vaccines","zoonoses"],"locations":["Wuhan","China","China","China","Philippines"],"countries":["Philippines","China"],"countries_codes":["PHL|Philippines","CHN|China"],"topics":["Mechanism","Transmission","Treatment","Diagnosis"],"weight":1,"_version_":1666138490874626048,"score":54.00098}]}